

September 2018

Corporate News



- Samumed entered into its first pharma partnership, exclusively licensing North American rights of SM04646 to treat idiopathic pulmonary fibrosis (IPF) to United Therapeutics Corporation
- Deal terms include \$10M up-front, plus up to \$340M in developmental milestones, and up to low double-digit royalties

Musculoskeletal Franchise Update



- 7 conference presentations have been accepted for our osteoarthritis and tendinopathy programs: 3 at the American College of Rheumatology (ACR) Annual Meeting, and 4 at the Bone, Muscle & Joint Diseases (BMJD) World Congress
- The above acceptances bring our total musculoskeletal presentations to date to 81 over the last few years; view them [here](#).

Clinical Operations Update



- We continue to expand our clinical development team to both prepare for our upcoming pivotal trials in osteoarthritis, as well as advance the rest of our portfolio
- To this end, we are actively hiring for senior positions across all clinical functions and have initiated the hiring of SamU3, the third cohort of our in-house clinical research associates